FindTrial
Sign In

Td vaccine

DRUG5 trials

Sponsors

Baylor College of Medicine, University of Florida

Conditions

Brain Stem GliomaDiffuse Intrinsic Pontine Glioma (DIPG)High Grade GliomaMalignant GliomaProgressive OligodendrogliomaRecurrent Group 3 MedulloblastomaRecurrent Group 4 (Non-SHH/Non-WNT) MedulloblastomaRecurrent Oligodendroglioma

Early Phase 1

Entolimod, an Adjuvant for Vaccine Augmentation
CompletedNCT03063736
Baylor College of MedicineSubstance Use Disorders
Start: 2017-12-08End: 2019-12-31Updated: 2020-09-01

Phase 1

Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas
TerminatedNCT03334305
University of FloridaHigh Grade Glioma, Malignant Glioma
Start: 2018-08-27End: 2025-03-20Updated: 2026-04-23
Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)
TerminatedNCT03396575
University of FloridaBrain Stem Glioma, Diffuse Intrinsic Pontine Glioma (DIPG)
Start: 2018-07-17End: 2025-03-20Updated: 2025-10-29
ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients
RecruitingNCT06254326
University of FloridaProgressive Oligodendroglioma, Recurrent Oligodendroglioma
Start: 2024-09-19End: 2028-06-01Target: 12Updated: 2026-05-27
Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma
RecruitingNCT06514898
University of FloridaRecurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma
Start: 2025-05-05End: 2028-12-01Target: 12Updated: 2026-08-07

Related Papers

IMMU-27. IMMUNE CHECKPOINT BLOCKADE OF EX VIVO EXPANDED T CELLS FOR USE IN ADOPTIVE CELLULAR THERAPY (ACT) FOR GLIOBLASTOMA
Neuro-Oncology2019-11-01
Abstract 1194: Adoptive cellular therapy overcomes tumor-induced dysregulation of myelopoiesis
Cancer Research2019-07-01
Abstract 1194: Adoptive cellular therapy overcomes tumor-induced dysregulation of myelopoiesis
Tumor Biology2019-07-01
TMIC-29. REPROGRAMMING BONE MARROW OF TUMOR-BEARING HOSTS FOR GLIOMA IMMUNOTHERAPY
Neuro-Oncology2018-11-01